Acasti Pharma Inc. (ACST)
NASDAQ: ACST · IEX Real-Time Price · USD
2.900
+0.030 (1.05%)
At close: Apr 24, 2024, 3:55 PM
3.010
+0.110 (3.79%)
After-hours: Apr 24, 2024, 6:35 PM EDT
Acasti Pharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Acasti Pharma stock has a target of 6.00, which predicts an increase of 106.90% from the current stock price of 2.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 7, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Acasti Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +106.90% | Feb 7, 2024 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +417.24% | Feb 15, 2023 |
| EF Hutton | EF Hutton | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +417.24% | Dec 19, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +396.55% | Dec 15, 2022 |
| Oppenheimer | Oppenheimer | Buy Initiates $36 | Buy | Initiates | $36 | +1,141.38% | Dec 22, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.98
from -5.70
EPS Next Year
-1.54
from -1.98
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 1.3M | 40.9M | 74.9M | 104.2M |
| Avg | n/a | n/a | 1.2M | 39.7M | 72.8M | 101.2M |
| Low | n/a | n/a | 1.2M | 38.2M | 69.9M | 97.2M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | 3,201.9% | 88.5% | 43.2% |
| Avg | - | - | - | 3,107.7% | 83.1% | 39.1% |
| Low | - | - | - | 2,981.8% | 76.0% | 33.6% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -2.03 | -1.59 | -1.44 | -0.17 | 0.63 | 1.60 |
| Avg | -1.98 | -1.54 | -1.40 | -0.16 | 0.61 | 1.56 |
| Low | -1.90 | -1.48 | -1.35 | -0.16 | 0.59 | 1.50 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | - | - | 162.6% |
| Avg | - | - | - | - | - | 155.1% |
| Low | - | - | - | - | - | 145.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.